Mayne Pharma Group Limited (ASX: MYX) announced the launch of the full range of clozapine tablets (25mg, 50mg, 100mg and 200mg) in the United States. Clozapine tablets are a generic alternative to Clozaril®, indicated as an antipsychotic.
Mayne Pharma’s CEO Scott Richards said, “The launch of the full range of Clozapine tablets is our 6 th product launch in 2017 and will further diversify our product offering. This product which is currently manufactured by Teva Pharmaceuticals Industries Limited, will ultimately be manufactured at our facility in Greenville, North Carolina and benefit from the investment underway to expand capacity. The new solid oral dose manufacturing facility is poised to open in early 2018 and will quadruple the Company’s U.S. manufacturing capacity to well over 1 billion doses, and importantly introduces significant new capacity to manufacture high potent compounds and new capability to manufacture modified-release bead/pellet products.”
Mayne Pharma directly markets more than 55 products and has a growing pipeline of more than 40 drug products targeting U.S. markets with QuintilesIMS sales greater than $6.5 billion. According to QuintilesIMS, annual US sales of clozapine tablets were approximately US$125 million for the 12 months ending 31 August 2017.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.